Can surgical treatment in the future be abandoned in breast cancer patients with a complete morphopathological response after neoadjuvant chemotherapy?

[1]  K. K. van de Vijver,et al.  Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study , 2020, Annals of Surgical Oncology.

[2]  W. Han,et al.  Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial , 2020, Breast Cancer Research and Treatment.

[3]  Z. Wang,et al.  The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer. , 2020, Quantitative imaging in medicine and surgery.

[4]  Houpu Yang,et al.  Could axillary clearance be avoided in clinically node-negative breast cancer patients with positive nodes diagnosed by ultrasound guided biopsy in the post-ACOSOG Z0011 era? , 2019, PloS one.

[5]  M. Golatta,et al.  RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial , 2018, BMC Cancer.

[6]  Vivek Verma,et al.  Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy , 2018, Breast Cancer Research and Treatment.

[7]  Tanya W. Moseley,et al.  Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints , 2018, Annals of Surgical Oncology.

[8]  Bonnie N. Joe,et al.  Imaging Neoadjuvant Therapy Response in Breast Cancer. , 2017, Radiology.

[9]  J. Wesseling,et al.  MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy , 2017, Breast Cancer Research and Treatment.

[10]  N. Udvarhelyi,et al.  Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  A. Schneeweiss,et al.  Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade , 2016, Breast Cancer Research and Treatment.

[12]  Т. И. Грушина,et al.  Психологический дистресс у больных раком молочной железы после различных видов противоопухолевого лечения , 2016 .

[13]  H. Kuerer,et al.  Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials , 2016, Breast Cancer Research.

[14]  G. Rauch,et al.  Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques , 2015, British Journal of Cancer.

[15]  P. Fasching,et al.  Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma , 2014, Breast Cancer Research and Treatment.

[16]  Nola Hylton,et al.  Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2013, Annals of Surgical Oncology.

[17]  Petra Macaskill,et al.  Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. , 2012, European journal of cancer.

[18]  T. Julian,et al.  Accuracy of Clinical Examination, Digital Mammogram, Ultrasound, and MRI in Determining Postneoadjuvant Pathologic Tumor Response in Operable Breast Cancer Patients , 2011, Annals of Surgical Oncology.

[19]  A. Soran,et al.  MRI Staging After Neoadjuvant Chemotherapy for Breast Cancer: Does Tumor Biology Affect Accuracy? , 2011, Annals of Surgical Oncology.

[20]  F. Vicini,et al.  Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy , 2007, Cancer.

[21]  A. Zikiryakhodzhaev,et al.  Experience in using the International Classification of Functioning, Disability and Health in patients with breast cancer after surgical treatment , 2018 .